Effective, convenient solutions for Female Sexual Interest/Arousal Disorder
Our mission is to provide women with pharmaceutical solutions for Female Sexual Interest/Arousal Disorder (FSIAD) to help them feel like themselves again.
FSIAD is a type of sexual dysfunction characterized by a lack of, or significantly reduced, sexual interest and/or arousal. As with other types of sexual dysfunction, FSIAD can be distressing and can affect a person’s self-esteem, relationships, and overall well-being.
Want to learn more about FSIAD?
LATEST NEWS
Women's experiences withFemale Sexual Interest/Arousal Disorder
Low desire is the most commonly
reported sexual complaint among women (Laumann et al. 1999, Laumann et al. 2005, Shifren et al. 2008, McCabe et al. 2015, Zheng et al. 2016)
Many women don’t know that
low sexual desire is a treatable
medical condition
(Kingsberg 2014)
Women’s options for sexual disorder
treatments are more than
20 years behind options for men
Women's sexual health is complex - treatments for fsiad must be more than a one-size-fits-all
Freya’s approach to treatment is guided by an understanding of the neurobiological mechanisms that are key in sexual excitation and inhibition. Our flagship product, Lybrido, is designed for patients with FSIAD who are relatively insensitive to sexual cues. Lybrido was developed from 15 years of research, and our clinical studies have shown statistically and clinically relevant improvements in women’s sexual experiences with its use.
Read more about the science behind Lybrido
Women's sexual health is complex - treatments for fsiad must be more than a one-size-fits-all
Freya’s approach to treatment is guided by an understanding of the neurobiological mechanisms that are key in sexual excitation and inhibition. Our flagship product, Lybrido, is designed for patients with FSIAD who are relatively insensitive to sexual cues. Lybrido was developed from 15 years of research, and our clinical studies have shown clinically relevant and statistically significant improvements in women’s sexual experiences with its use.
Read more about the science behind Lybrido
Upcoming events
25th European Society for Sexual Medicine (ESSM) Congress 2023
February 16-18, 2023 | Rotterdam, The Netherlands
28th Annual Scientific Program of the Sexual Medicine Society of North America (SMSNA)
April 28, 2023 | Chicago, USA
ICSM 2023: 17. International Conference on Sexual Medicine
August 17-18, 2023 | Kuala Lumpur, Malaysia
Nordic Association for Clinical Sexology (NACS) Conference 2023
September 28 – October 1, 2023 | Oslo, Norway
Women's experiences withFemale Sexual Interest/Arousal Disorder
Low desire is the most commonly
reported sexual complaint among women
(Laumann et al. 1999, Laumann et al. 2005,
Shifren et al. 2008, McCabe et al. 2015,
Zheng et al. 2016)
Many women don’t know that
low sexual desire is a
treatable medical condition
(Kingsberg 2014)
Women’s options for sexual disorder
treatments are more than
20 years behind options for men
Upcoming events
25th European Society for Sexual Medicine (ESSM) Congress 2023
February 16-18, 2023 | Rotterdam, The Netherlands
28th Annual Scientific Program of the Sexual Medicine Society of North America (SMSNA)
April 28, 2023 | Chicago, USA
ICSM 2023: 17. International Conference on Sexual Medicine
August 17-18, 2023 | Kuala Lumpur, Malaysia
Nordic Association for Clinical Sexology (NACS) Conference 2023
September 28 – October 1, 2023 | Oslo, Norway
Freya Pharma Solutions B.V.
Kraanspoor 50 | 1033 SE Amsterdam | The Netherlands
info@freyapharmasolutions.com
Freya Pharma Solutions B.V.
B.V. Kraanspoor 50 | 1033 SE Amsterdam | The Netherlands
info@freyapharmasolutions.com
All rights reserved.